This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
What's in Store for Intuitive Surgical (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) Q1 earnings are likely to reflect better-than-expected performance at Instruments & Accessories segment and da Vinci procedure growth.
Will COVID-19 Test Aid Quest Diagnostics (DGX) Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) recently-launched COVID-19 test service anticipated to have contributed to Q1 revenues.
Amedisys Gains on Expanding Hospice Arm, Favorable Demography
by Zacks Equity Research
Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.
Intersect Posts Preliminary Q1 Results, Withdraws '20 View
by Zacks Equity Research
Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.
Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month
by Nalak Das
Despite the economic disaster, a few stocks are likely to report better-than expected earnings results when they report their financial numbers this month.
Will Brand Building Efforts Aid Aphria (APHA) in Q3 Earnings?
by Zacks Equity Research
Aphria's (APHA) focus on enhancing its brands and profitability is likely to have boosted its top line in third-quarter fiscal 2020.
Solid Diagnostics to Aid Abbott (ABT) Q1 Earnings Amid Crisis?
by Zacks Equity Research
Though the magnitude of loss due to the virus outbreak in Abbott's (ABT) Core Laboratory business is still unclear, the company's point-of-care business is anticipated to generate profit.
Here's Why You Should Retain Allscripts in Your Portfolio Now
by Zacks Equity Research
Investor confidence remains high in Allscripts' (MDRX) stock, thanks to solid prospects.
Can Product Innovation Aid OrganiGram (OGI) in Q2 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and ongoing product innovation in the fiscal second quarter.
PRA Health Unit to Offer Free Access to Metys COVID-19 Module
by Zacks Equity Research
PRA Health's (PRAH) new module is likely to boost Data Solutions segment.
Will Low Product Revenues Impact Abbott (ABT) Q1 Earnings?
by Zacks Equity Research
Revenues of Abbott's (ABT) Diabetes Care business, which has been, otherwise on a strong growth trajectory, are likely to have declined in Q1 due to the coronavirus-related market turbulence.
Here's Why You Should Retain HealthEquity Stock for Now
by Zacks Equity Research
Investor confidence remains high in HealthEquity (HQY) stock, thanks to solid prospects.
Merit Medical WRAPSODY Gets 2 FDA Breakthrough Device Nods
by Zacks Equity Research
This regulatory clearance is expected to bolster Merit Medical Systems' (MMSI) cardiovascular segment.
Here's Why You Should Retain AMN Healthcare (AMN) for Now
by Zacks Equity Research
Investor confidence remains high on AMN Healthcare's (AMN) stock, thanks to solid prospects.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in Surmodics' (SRDX) stock,thanks to solid prospects.
Here's Why You Should Add DexCom (DXCM) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in DexCom's (DXCM) stock, thanks to solid prospects.
Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now
by Benjamin Rains
DexCom shares have soared 45% since March 18. The connected glucose monitoring systems firm is also expected to continue to grow and DXCM stock might be somewhat immune to the current coronavirus economic uncertainty...
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
What Stocks Move After the Stimulus Bill Passes?
by John Blank
The U.S. economy can recover (quicker) with this bill.
US Government Reaches Deal on Stimulus Package: 5 Top Picks
by Nalak Das
The U.S. government and Senate reached an agreement to inject $2 trillion of stimulus to boost the U.S. economy amid the coronavirus-induced turmoil.
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $209.50, marking a +1.58% move from the previous day.
The Zacks Analyst Blog Highlights: HP, DexCom and Western Digital
by Zacks Equity Research
The Zacks Analyst Blog Highlights: HP, DexCom and Western Digital